Williams Cancer Institute

Innovative SYNC-T SV-102 Therapy: A Breakthrough in Prostate Cancer Treatment

Syncromune® Inc., a pioneering clinical-stage biopharmaceutical company, is advancing the field of oncology with its cutting-edge SYNC-T SV-102 Therapy. This novel treatment combines partial tumor oncolysis with a fixed-dose multi-target biologic drug, offering a personalized approach for metastatic castrate-resistant prostate cancer.

Key Developments and Trial Initiation

Syncromune is set to begin patient enrollment for the LEGION-100 Phase 1b trial in the second half of 2024, focusing on metastatic castrate-resistant prostate cancer. The trial’s initiation follows the U.S. Food and Drug Administration’s (FDA) clearance of the investigational new drug (IND) application for SYNC-T SV-102, marking a significant milestone in the therapy’s development.

Leadership and Vision

“Achieving IND clearance is a pivotal moment for Syncromune, propelling us forward in the clinical development of SYNC-T SV-102,” stated Eamonn Hobbs, President and CEO of Syncromune. “This milestone, combined with our recent data showcasing remarkable response rates, highlights SYNC-T SV-102’s potential to revolutionize prostate cancer treatment.”

Charles Link, M.D., Executive Chairman of Syncromune, echoed this enthusiasm, emphasizing the broad applicability of this innovative multi-target approach in treating metastatic solid tumor cancers. “The prospects of this combination therapy are incredibly exciting,” he added.

SYNC-T Platform: Personalized and Innovative Approach

The SYNC-T platform stands out as a personalized in situ therapy, leveraging a unique method that integrates partial tumor oncolysis with a multi-target biologic drug composed of four active pharmaceutical ingredients (APIs). The therapy begins with oncolysis, where freezing disrupts a portion of the target tumor, releasing cancer-specific signals and tumor antigens. This process activates the immune system, creating an in situ vaccine.

Following this, the multi-target biologic drug SV-102 is directly infused into the tumor site to further stimulate the immune system and inhibit mechanisms that suppress immune response. This combination is designed to enhance T cell activation and proliferation, enabling the immune system to recognize and combat patient-specific cancer cells throughout the body.

Promising Clinical Results

In a Phase 1 trial involving patients with metastatic castrate-resistant prostate cancer, SYNC-T SV-102 demonstrated an impressive objective response rate (ORR) of 85%. Among the 13 evaluable subjects, five achieved complete responses (CRs), and six showed partial responses (PRs). Notably, 54% of the patients experienced complete resolution of their bone metastases. The treatment was well tolerated, presenting a favorable side effect profile with no significant safety concerns.

Looking Forward

With the FDA’s IND clearance and the upcoming Phase 1b trial, Syncromune is poised to make significant strides in cancer therapy. The innovative SYNC-T SV-102 Therapy represents a beacon of hope for patients battling metastatic castrate-resistant prostate cancer, offering a promising new approach that could transform the landscape of cancer treatment.

Stay tuned as Syncromune continues to push the boundaries of oncology, driven by a commitment to innovative, personalized care for cancer patients.

Reference: Syncromune. (2024, mayo 30). Syncromune, inc. Announces FDA clearance of IND application for SYNC-T SV-102, a first-in-class combination multi-target immunotherapy for metastatic castrate-resistant prostate cancer. Yahoo Finance. https://finance.yahoo.com/news/syncromune-inc-announces-fda-clearance-232200345.html

Related Posts

Blog 18 de Julio de 2024
Blog 16 de Julio de 2024
bLog 11 de Julio de 2024
1 2 3 114